We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Netflix, Salesforce, Novo Nordisk, Caterpillar and ConocoPhillips
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 9, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Caterpillar, Inc. (CAT - Free Report) , ConocoPhillips (COP - Free Report) , Netflix, Inc. (NFLX - Free Report) , salesforce.com, inc. (CRM - Free Report) , and Novo Nordisk A/S (NVO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Netflix, salesforce and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Salesforce, and Novo Nordisk. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Netflix shares have gained +15.7% in the year-to-date period against the Zacks Broadcast Radio and Television industry’s gain of +8.8%. The Zacks analyst believes that Netflix is dominating the streaming space, courtesy of its diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content.
The launch of low-priced mobile plans is likely to expand Netflix’s subscriber base in the Asia-Pacific region. Moreover, a solid content slate and resumption of production is expected to aid Netflix’s prospects in the rest of 2021 and beyond. However, rising competition from Apple, Amazon, HBO Max, Disney+ and Peacock is a major headwind. Netflix’s leveraged balance sheet and higher streaming obligation is a concern.
Shares of salesforce have underperformed the Zacks Computer - Software industry over the past year (+21.1% vs. +46.4%), however, things seem to be improving for it. The Zacks analyst believes that the company is benefiting from a robust demand environment as customers are undergoing a major digital transformation.
The rapid adoption of its cloud-based solutions is driving demand for its products. The company’s sustained focus on introducing more aligned products as per customer needs is driving its top-line.
Continued deal wins in the international market is another growth driver. Furthermore, the recent acquisition of Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft’s Teams product.
However, stiff competition is a concern. Unfavorable currency fluctuations along with increasing investments in international expansions and data centers are an overhang on near-term profitability.
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry in the year to date period (+57.7% vs. +13.0%). The Zacks analyst believes that the company’s Novo Nordisk has one of the broadest diabetes portfolios in the industry.
Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs will further boost sales. Novo Nordisk’s existing drugs for obesity along with recently approved products are boosting the top line.
However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Sales are also being negatively impacted by the COVID-19 pandemic, which is a woe.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Netflix, Salesforce, Novo Nordisk, Caterpillar and ConocoPhillips
For Immediate Release
Chicago, IL – December 9, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Caterpillar, Inc. (CAT - Free Report) , ConocoPhillips (COP - Free Report) , Netflix, Inc. (NFLX - Free Report) , salesforce.com, inc. (CRM - Free Report) , and Novo Nordisk A/S (NVO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Netflix, salesforce and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Salesforce, and Novo Nordisk. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Netflix shares have gained +15.7% in the year-to-date period against the Zacks Broadcast Radio and Television industry’s gain of +8.8%. The Zacks analyst believes that Netflix is dominating the streaming space, courtesy of its diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content.
The launch of low-priced mobile plans is likely to expand Netflix’s subscriber base in the Asia-Pacific region. Moreover, a solid content slate and resumption of production is expected to aid Netflix’s prospects in the rest of 2021 and beyond. However, rising competition from Apple, Amazon, HBO Max, Disney+ and Peacock is a major headwind. Netflix’s leveraged balance sheet and higher streaming obligation is a concern.
(You can read the full research report on Netflix here >>>)
Shares of salesforce have underperformed the Zacks Computer - Software industry over the past year (+21.1% vs. +46.4%), however, things seem to be improving for it. The Zacks analyst believes that the company is benefiting from a robust demand environment as customers are undergoing a major digital transformation.
The rapid adoption of its cloud-based solutions is driving demand for its products. The company’s sustained focus on introducing more aligned products as per customer needs is driving its top-line.
Continued deal wins in the international market is another growth driver. Furthermore, the recent acquisition of Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft’s Teams product.
However, stiff competition is a concern. Unfavorable currency fluctuations along with increasing investments in international expansions and data centers are an overhang on near-term profitability.
(You can read the full research report on salesforce here >>>)
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry in the year to date period (+57.7% vs. +13.0%). The Zacks analyst believes that the company’s Novo Nordisk has one of the broadest diabetes portfolios in the industry.
Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs will further boost sales. Novo Nordisk’s existing drugs for obesity along with recently approved products are boosting the top line.
However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Sales are also being negatively impacted by the COVID-19 pandemic, which is a woe.
(You can read the full research report on Novo Nordisk here >>>)
Other noteworthy reports we are featuring today include Caterpillar and ConocoPhillips.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.